Key result
Alirocumab therapy for 6 months in Chinese patients with acute coronary syndrome significantly increased the percentage achieving LDL-C <1.0 mmol/L compared to baseline (51.3% vs 1.4%, P<0.0001).
Why the study?
Guidelines recommend in-hospital high-intensity statins for ACS, but LDL-C targets are frequently missed, and real-world evidence for alirocumab in Chinese ACS patients is scarce.
Does alirocumab improve the achieved rate of LDL-C targets in Chinese patients with acute coronary syndrome?
Observational (n=73)
No
Does alirocumab improve the achieved rate of LDL-C targets in Chinese patients with acute coronary syndrome?
Absolute Event Rate: 51.3% vs 1.4%
p-value: p=<0.0001
In a real-world cohort of Chinese patients with ACS, alirocumab significantly improved the attainment of stringent LDL-C targets (<1.0 and <1.4 mmol/L) at 6 months.
Alirocumab was associated with higher LDL-C goal attainment in Chinese ACS patients; leaves open need for randomized outcome trials.
AIMS: Although guidelines recommend in-hospital initiation of high-intensity statin therapy in patients with acute coronary syndromes (ACS), low-density lipoprotein cholesterol (LDL-C) target levels are frequently not attained. Alirocumab has been demonstrated to be a fast-acting and efficacious agent for lowering LDL-C in controlled trials. However, there is a paucity of real-world evidence concerning its use in patients of Chinese ethnicity with ACS. This real-world observational study aimed to assess the efficacy and safety of alirocumab in Chinese ACS patients. METHODS: This study is a single-centre, retrospective study involving 73 patients with ACS treated with alirocumab over 6 months, followed up at 1, 3, 6 and 12 months, the main observation measure is the achieved rate of LDL-C levels after treatment with alirocumab at 6 months. RESULTS: In comparison with baseline, alirocumab therapy for 6 months was associated with a significant increase in percentage of patients who attained the control goal of LDL-C <1.0 mmol/L (51.3 vs. 1.4%, P < .0001) and <1.4 mmol/L (61.5 vs. 5.5%, P < .0001), respectively. CONCLUSION: There was a significant reduction in LDL-C levels with alirocumab with or without lipid-lowering therapy treatment in ACS patients in this real-world evidence study. The percentage of patients achieving LDL-C goals of <1.00 and <1.40 mmol/L were significantly higher than baseline 6 months after the adding alirocumab.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) conducted an observational in Acute coronary syndrome (n=73). Alirocumab vs. Baseline was evaluated on Achieved rate of LDL-C levels <1.0 mmol/L at 6 months (p=<0.0001). Alirocumab therapy for 6 months in Chinese patients with acute coronary syndrome significantly increased the percentage achieving LDL-C <1.0 mmol/L compared to baseline (51.3% vs 1.4%, P<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: